Impact of Image-based Motion Correction on Dopamine D3/D2 Receptor Occupancy – Comparison of Groupwise and Frame-by-Frame Registration Approaches

Jieqing Jiao\textsuperscript{1,2}, Graham E. Searle\textsuperscript{2}, Julia A. Schnabel\textsuperscript{1,4} and Roger N. Gunn\textsuperscript{1,2,3,4}

\textsuperscript{1}Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, UK
\textsuperscript{2}Imanova Limited, Hammersmith Hospital, London, UK
\textsuperscript{3}Department of Medicine, Imperial College, London, UK
\textsuperscript{4}These authors jointly directed this work.

Corresponding author:
Roger Gunn
Imanova
2\textsuperscript{nd} Floor, Burlington Danes Building
Imperial College London
Du Cane Road
London, U.K., W12 0NN
Email: roger.gunn@imanova.co.uk
Tel: +44 (0) 2080086027
Fax: +44 (0) 2080086027

Running headline: Impact of Motion Correction on Occupancy Study
Abstract

Background
Image registration algorithms are frequently used to align the reconstructed brain PET frames to remove subject head motion. However, in occupancy studies this is a challenging task where competitive binding of a drug can further reduce the available signal for registration. The purpose of this study is to evaluate two kinds of algorithms - a conventional frame-by-frame (FBF) registration and a recently introduced groupwise image registration (GIR), for motion correction of a dopamine D3/D2 receptor occupancy study.

Methods
The FBF method co-registers all the PET frames to a common reference based on normalised mutual information as the spatial similarity. The GIR method incorporates a pharmacokinetic model and conducts motion correction by maximising a likelihood function iteratively on tracer kinetics and subject motion. Data from 8 healthy volunteers scanned with [11C]-(+)-PHNO pre- and post-administration of a range of doses of the D3 antagonist GSK618334 were used to compare the motion correction performance.

Results
The groupwise registration achieved improved motion correction results, both by visual inspection of the dynamic PET data and by the reduction of the variability in the outcome measures, and required no additional steps to exclude unsuccessfully realigned PET data for occupancy modelling as compared to frame-by-frame registration. Furthermore, for the groupwise method, the resultant binding potential estimates had reduced variation and bias for individual scans, and improved EC50 estimates were obtained for the study as a whole.

Conclusions
These results indicate that the groupwise registration approach can provide improved motion correction of dynamic brain PET data as compared to frame-by-frame registration approaches for receptor occupancy studies.

**Keywords:** PET, motion correction, groupwise registration, pharmacokinetic modeling, receptor occupancy studies
1. Background

Dynamic PET brain scans are susceptible to head motion that distorts the tissue-to-voxel mapping and this leads to degraded PET images from acquisitions that can last up to 2 hours. If uncorrected, motion induced attenuation correction mismatch, inter-frame misalignment and intra-frame blurring in the PET data will make the quantification of the tracer kinetic data unreliable [1]. Previous approaches to the motion problem have included the use of head restraints or external motion tracking systems that have been developed to try to record the motion parameters [2-5]. However, these methods have limitations either due to patient discomfort, accuracy or ease of use.

Meanwhile, image-based computational methods have been developed to establish the spatial correspondences between PET data at different time frames [6-8], allowing for post-acquisition corrections to be applied. Such methods perform a rigid frame-by-frame (FBF) image registration of PET time frames to a common reference image, which is usually a PET image derived from a single frame, a weighted sum of frames or an associated magnetic resonance (MR) image for the subject. The FBF registration methods have been widely used for motion correction in recent studies [9-12] due to the ease of implementation based on existing publicly available image registration software packages, such as SPM (used in [13]), AIR (used in [14]), FLIRT (used in [15]), and the commercial software PMOD. FBF methods are shown to improve the integrity of PET data, but have potential limitations that need consideration. For example, the FBF registration is solely based on maximising the spatial similarities between images and it can converge to inaccurate solutions in the presence of noise [16].
Recently, a groupwise image registration (GIR) framework for dynamic PET data has been introduced for motion correction [17, 18]. The GIR method enables noise modelling, and accounts for tracer kinetics by incorporating a pharmacokinetic model with either an arterial input function (AIF) [18], or a reference tissue input function [17]. Improved registration results as compared to FBF methods have been demonstrated in simulation-based validations. This work aims to evaluate the motion correction performance of these image-based methods on an occupancy study where the competitive binding can impose further challenges for conducting image registration on the PET images. Data from a dopamine D3/D2 receptor occupancy study with [11C]-(+)-PHNO were used. The study was designed to measure the half maximal effective concentration (EC$_{50}$) of the D3 antagonist GSK618334. For the reconstructed PET time frames, three separate approaches to motion were applied: 1) no motion correction, 2) frame-by-frame motion correction, and 3) groupwise image registration motion correction with a reference tissue input. Following motion correction, kinetic analysis was applied to each dataset to derive regional binding potential estimates for each scan and then modeling of the competitive binding of the drug to derive its EC$_{50}$ was performed using all scans in the study.

2. **Methods**

2.1. **Human [11C]-(+)-PHNO PET study**

The motion correction algorithms were evaluated on [11C]-(+)-PHNO PET occupancy data involving a range of doses of the antagonist GSK618334. Data from eight subjects, from a previously reported study [19], were used here. All subjects were healthy, male, drug-free, non-smoking volunteers, aged between 25 and 55 years, with body weights and BMI in the normal range. All subjects gave written informed consent, and their eligibility was confirmed via medical history, physical examinations and standard tests. Further details of the inclusion and exclusion criteria can be found
on www.clinicaltrial.gov by reference to NCT00814957, and the study was approved by East of England Hatfield REC (known as NRES Committee East of England - Welwyn at the time of the study). Each subject received a baseline PET scan, then a single oral dose of 5–550 mg of GSK618334 followed by two further PET scans performed between 1.5 and 29 hours post-administration of GSK618334. Venous blood was sampled for measurements of GSK618334 plasma concentration. The [11C]-(+)-PHNO PET scans were acquired using a Siemens Biograph 6 PET-CT with Truepoint gantry in 3D-mode, and then reconstructed using filtered back projection with corrections for dead time, random coincidences, variations in detector sensitivity, attenuation (based on a low-dose CT acquisition) and scatter. The reconstruction had the measured resolution of 9mm (transaxial) and 7mm (axial) in full width at half maximum at the centre of the field of view, and after reconstruction the PET images were filtered with a Gaussian filter of 5mm in full width at half maximum in the 3 orthogonal planes. Dynamic data were acquired using 26 frames (durations: 8×15 s, 3×1 min, 5×2 min, 5×5 min, 5×10 min). Arterial blood data was also acquired and enabled plasma input based modelling to be applied for determination of the final BP
ND regional outcome measures of interest. Each subject also received a high resolution T1-weighted MR scan with a Siemens Tim Trio 3T scanner (Siemens Healthcare, Erlangen, Germany). A U-shaped head holder with foam padding designed to snugly hold the subject’s head in place laterally, with a soft Velcro strap across the forehead to aid as a reminder to the subject, was used in this study.

2.2. Frame-by-frame (FBF) motion correction

The FBF method co-registers all the PET frames to a common reference based on spatial similarity. The PET frame acquired between 13-15 mins in the scan was used as the reference frame and normalised mutual information (NMI) was used as the cost function. The settings of the FBF method used in this work have been optimised in our previous internal investigations. Frame 13-15 min was selected based on
previous (unpublished) work which optimised the method by evaluating the performance using a range of possible reference frames for \([11\text{C}]-(+)-\text{PHNO}\). The image of \([11\text{C}]-(+)-\text{PHNO}\) at this time in the scan contains features that are common to both early distribution and later binding phases. Although the duration of this frame (2 mins) is short, it balances the desire to select a frame with minimal motion whilst capitalising on the high imaging statistics at this time in conjunction with representation of all the key image features. The FBF algorithm was implemented in MATLAB 7.7, using functions available within Statistical Parametric Mapping (SPM8, http://www.fil.ion.ucl.ac.uk/spm/) with the default settings for the optimisation, interpolation, image smoothing and histogram smoothing.

2.3. Groupwise image registration (GIR) motion correction

The proposed GIR algorithm conducts motion correction by solving the maximum likelihood problem. Assuming the measurement is distributed as a multivariate Gaussian, the likelihood of the measured dynamic PET data \(Y\) can be formulated as

\[
L(\Phi; T; Y) = \prod_{j=1}^{M} \prod_{k=1}^{F} \frac{1}{\sqrt{2\pi\sigma^2(x_j,k)}} \exp\left(-\frac{(Y(T^{-1}_k(x_j), t_k) - Y_{\phi}(x_j, t_k))^2}{2\pi\sigma^2(x_j,k)}\right)
\]

(1)

where \(Y_{\phi}\) is the predicted PET data determined by the tracer kinetic parameter \(\Phi\), \(T_k\) is the spatial transformation that corrupts the voxel-to-tissue mapping for the k-th frame, \(\sigma^2(x_j,k)\) is the variance term describing the measurement noise level, \(M\) and \(F\) are the numbers of voxels and time frames respectively.

The unknown \(T\) and \(\Phi\) can be optimised iteratively until convergence. For brain images, \(T\) describes the rigid head motion using three translations and three rotations. \(Y_{\phi}\) can be described by the generalised reference tissue model embedded in a basis function framework and solved by the method of basis pursuit denoising [20] as follows.
Let $C_T(t)$ be the tracer concentration time course in the target tissue, then $C_T(t)$ can be expressed as an expansion on a basis as

$$C_T(t) = \phi_0 C_R(t) + \sum_{i=1}^{N} \phi_i \psi_i,$$

where $\psi_i = e^{-\theta_i t} \otimes C_R(t)$ and $C_R(t)$ is the tracer concentration time course in the reference tissue. A discrete set of values can be selected for $\theta_i$ from a physiologically plausible range spaced in a logarithmic manner to elicit a suitable coverage of the kinetic spectrum. The measured PET data $Y(x,t)$ corresponds to $C_T(t)$ as

$$Y(x_j,t_k) = \frac{1}{t_k^e - t_k^s} \int_{t_k^s}^{t_k^e} C_T(t) dt = Y_{x,j},$$

where $t_k^s$ and $t_k^e$ are the start and end times for the $k$-th frame ($k = 1 \cdots F$).

Accordingly, the basis functions can be written as

$$\psi_{0,k} = \frac{1}{t_k^e - t_k^s} \int_{t_k^s}^{t_k^e} C_R(t) dt$$

$$\psi_{i,k} = \frac{1}{t_k^e - t_k^s} \int_{t_k^s}^{t_k^e} e^{-\theta_i t} \otimes C_R(t) dt \quad i = 1 \cdots N$$

The unknown tracer kinetic parameter matrix of the image $\Phi$ can then be determined by solving $Y = \Psi \Phi$. In practice, to account for the uncertainty of the measurements, the weighted least squares problem

$$W^2 Y = W^2 \Psi \Phi$$

can be considered, where $W$ is the inverse of the covariance matrix corresponding to the noise variance term $\sigma^2$ in Equation 1. The noise variance for decay corrected PET data can be modeled as $\sigma^2(k) = \sum_j Y(x_j,t_k) / (t_k^e - t_k^s) \times dcf(k)$, derived from the variance model 1 in [21], where $dcf(k) = \lambda(t_k^e - t_k^s) / [\exp(-\lambda t_k^e) - \exp(-\lambda t_k^s)]$. 

7
is the decay correction function and $\lambda$ is the decay constant of the isotope. Given the independence of the frames, $W$ is diagonal, and can be calculated as

$$W_{kk} = \frac{1}{\sigma^2(k)}.$$ 

The basis is typically overcomplete ($N > F - 1$) leading to an under-determined set of equations that basis pursuit denoising solves with the addition of a 1-norm penalty term [20]

$$\min_{\phi} \| W^{1/2}Y - W^{1/2}\Psi\Phi \|^2_2 + \mu \| \Phi \|$$

(5)

Here, $\mu > 0$ is a regularisation parameter which balances the approximation error and sparseness of $\Phi$ and imposes a unique solution. To avoid the difference in the scales, the basis functions are normalised here so that $\| \Psi_i \|_2 = 1$ for all $i$. We previously proposed an efficient way to determine the value for $\mu$ [17], and based on this approach we use a value of $\mu = 8.69$ for $[11C]-(+)-\text{PHNO}$.

This general reference tissue kinetic model is used as the pharmacokinetic model in the GIR method. It constrains the registration in a groupwise fashion by using the temporal information. The complete algorithm is summarised in Figure 1. Step 1 initialises the algorithm using the identity function for $T$. In Step 2, the discrete reference data is first extracted from the motion-corrected PET data $Y(T^{-1}(x), t)$ as a regional time activity curve from the anatomical reference region of choice, and the reference input function $C_R(t)$ is generated using linear interpolation. For the purpose of describing the tracer kinetics, rather than estimating the absolute parameters for binding or uptake, a region with low specific binding is mathematically appropriate for deriving the reference input. Step 3 calculates the basis functions which are convolutions of the reference tissue input and the pre-defined exponentials.
Step 4 solves the kinetic model fitting via basis pursuit denoising. In Step 5, the original motion-corrupted PET data $Y(x,t)$ is registered to the model-predicted PET data $Y_\phi$ to update the motion estimation $T$ and motion-corrected PET data $Y(T^{-1}(x),t)$. Steps 2-5 repeat until convergence, and the algorithm returns the motion-corrected PET data $Y(T^{-1}(x),t)$ in Step 6.

In this work, for kinetic modeling in the GIR motion framework, the reference input function was derived from grey matter of the cerebellum for the [11C]-(+)-PHNO PET data. The reference region was delineated via nonlinear registration using SPM8 (http://www.fil.ion.ucl.ac.uk/spm) of a predefined brain atlas to the subject's MRI (aligned to the PET image) to propagate the segmentation.

2.4. **Regional calculation of [11C]-(+)-PHNO $BP_{ND}$**

Regional analysis of $BP_{ND}$ and occupancy analysis was performed after 1) no motion correction, 2) FBF motion correction, and 3) GIR motion correction with reference tissue input. The [11C]-(+)-PHNO kinetics were analysed for six regions-of-interest (ROIs): substantia nigra (SN), globus pallidus (GP), ventral striatum (VST), dorsal caudate (CD), dorsal putamen (PU), thalamus (TH). These target ROIs were defined manually according to guidelines described previously [22]. GP, VST, CD, PU, TH were drawn on each subject's structural T1-weighted magnetic resonance imaging (MRI). The MR T1-weighted image was registered to the time-weighted integral of the dynamic PET images following motion correction using the rigid registration function in SPM8 with a mutual information cost function. SN was defined on each subject's baseline PET integral image given the insufficient contrast available from MRI data. Regional time-activity curves (TACs) were then derived for each ROI.
Subsequently, a two-tissue compartmental (2TC) plasma input model was applied to
the regional time activity curves to appropriately quantify regional [11C]-(+)-PHNO
volume of distribution \( (V_T) \) estimates in the basal ganglia ROIs [19]. This included a
fixed blood volume correction of 5%. Regional \( BP_{ROI}^{ND} \) estimates were then derived
for each of the target regions using cerebellum as the reference region,

\[
BP_{ROI}^{ND} = \frac{V_{ROI}}{V_{CER}^{T}}. 
\]

2.5. Competitive binding of drug and PHNO

The [11C]-(+)-PHNO occupancy study was designed to measure the dopamine D3
and D2 receptor occupancy of GSK618334 and requires the application of a two-site
competitive binding model [19]. Given the baseline binding potential, \( BP_{ND}^{base} \), the
binding potential following drug administration, \( BP_{ND}^{drug} \) and the plasma concentration
of the drug (GSK618334), \( C_{drug}^{P} \), then,

\[
BP_{ND}^{drug} = BP_{ND}^{base} \left( \frac{f_{PHNO} D3}{EC_{drug,D3}^{S0}} + \frac{1 - f_{PHNO} D3}{EC_{drug,D2}^{S0}} \right),
\]

where \( f_{PHNO} D3 \) is the regional fraction of baseline [11C]-(+)-PHNO \( BP_{ND} \)
corresponding to D3 binding with values of 0.87 for SN, 0.66 for GP, 0.39 for VST,
0.69 for TH, 0.21 for CD, 0.14 for PU [19], \( EC_{drug,D3}^{S0} \) and \( EC_{drug,D2}^{S0} \) are the plasma
concentrations of the drug (GSK618334) that would result in 50% occupancy of the
D3 and D2 receptor respectively.

Recent work has demonstrated that for true quantification it is necessary to account
for mass effects of [11C]-(+)-PHNO itself and a small displaceable specific signal in
the cerebellum in addition to competitive binding of the drug at D3 and D2 sites [19].
For the actual fitting of the $^{[11C]}$-(+)-PHNO $B_{PD}$ data, we used an extension of the competitive binding model in Equation 4 that includes corrections for PHNO mass dose effect at D3 sites and cerebellum specific binding [19]. This model is given in Supplementary Material. Note that when modelling the competitive binding, all regions were fitted simultaneously and the $EC^{\text{drug}.D3}_{50}$ and $EC^{\text{drug}.D2}_{50}$ parameters assumed constant across all regions and subjects [19].

3. Results

3.1. Motion correction of $^{[11C]}$-(+)-PHNO data

The GIR and FBF motion correction algorithms were applied on reconstructed $^{[11C]}$-(+)-PHNO PET data to address inter-frame misalignment caused by subject motion. PET data that had already been attenuation corrected was used due to the clinical pipeline and the use of PET data without attenuation correction will be considered in the Discussion. Firstly, visual inspection using the movie mode in FSLview (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/) was performed on the 24 scans obtained from the 8 healthy subjects without motion correction to derive an initial qualitative assessment of motion. In 4 scans, there was severe motion with up to 10 degree rotations or 40 mm translations. In 8 scans there was motion at the level of the voxel size (2mm), and in 12 scans the motion was difficult to detect. For the motion correction algorithms, a metric summarising the displacement was calculated for each time frame by using the estimated translation and rotation parameters,

$$
\text{displacement} = \sqrt{\frac{1}{M} \sum_{j=1}^{M} \|T(x_j) - x_j\|^2},
$$

where $T$ is the rigid transformation determined by the translations and rotations and $M$ is the number of all the voxels, and $x_j$ is the coordinate of voxel $j$. Figure 2 shows a summary of the displacements introduced by both FBF and GIR motion.
correction algorithms for the 24 scans. Whilst the individual reference frames for both the FBF and GIR methods may be different, we are interested in comparing the distributions of the displacements which should be insensitive to this. The computation time of the GIR motion correction algorithm depended on the amplitude of the motion and the image noise. On a desktop workstation (CPU 3.20GHz, 16GB RAM) with MATLAB 7.7, the GIR algorithm took between 20 and 90 mins of computation time for each 26-frame dynamic image; the FBF algorithm took in general 60 mins. No GPU or parallel computing was applied in this work.

Figure 3 and Figure 4 illustrate the performance of the GIR and FBF algorithms when registering [11C]-(+)-PHNO PET data from subjects with visually obvious motion. The motion artefact was well corrected by the GIR algorithm as indicated by the sagittal view of the PET data. Furthermore, for the baseline scan, the voxel-based TACs from dorsal caudate and globus pallidus shown on the sagittal slice are displayed before and after GIR motion correction together with the normalised population TACs for these ROIs. The population TACs were generated by averaging the baseline [11C]-(+)-PHNO PET data after motion correction over the eight healthy subjects, and were scaled according to dose and subject weight. The consistency with the normalised population data after MC by the GIR algorithm provides supporting evidence for the successful removal of the inter-frame misalignment caused by motion.

3.2. Binding potential of [11C]-(+)-PHNO
Regional estimates of [11C]-(+)-PHNO $BP_{ND}$ were derived for baseline and post-GSK618334 PET scans for SN, GP, VST, CD, PU and TH before and after motion correction. During the 2TC kinetic parameter estimation, 2 unrealistically large $V_T$ values were obtained for the data with no motion correction, 3 unrealistically large $V_T$ values were obtained after motion correction by FBF, whereas none were obtained
after MC by GIR. For the scans where there were unrealistic values of $V_T$, the motion correction error of FBF was not always visually detectable, suggesting that small residual motion can introduce significant errors into $V_T$ particularly for regions with slower kinetics such as the globus pallidus and ventral striatum. Corresponding $BP_{ND}$ values for baseline and post-dose scans are shown in Figure 5A with unrealistic values shown above the line breaks. After excluding the unrealistic data points considered as convergence failure, the inter-subject variability was assessed on baseline $BP_{ND}$ by the coefficient of variation (CV)

$$ CV = \frac{\sigma(BP_{ND})}{\mu(BP_{ND})} $$

where $\sigma$ and $\mu$ are the standard deviation and mean across the eight subjects. The CV values before motion correction, after motion correction by the FBF algorithm and by the proposed GIR algorithm are shown in Table 1, together with the ROI size in cm$^3$. These data provide further evidence for improved registration with GIR through the significant reduction in the CV of baseline $BP_{ND}$ data across all regions. It was also apparent that the conventional FBF algorithm could lead to subsequent convergence problems in the kinetic fitting, whereas the proposed GIR algorithm avoided such problems, thus eliminating the need to subjectively exclude outliers due to unsuccessful motion correction. The conventional FBF algorithm produced less of a reduction in CV (even after excluding unrealistic data).

3.3. Occupancy and estimation of the EC$_{50}$ of GSK618334

The $BP_{ND}$ of [11C]-(+)-PHNO measured in the follow up PET data, after dosing with GSK618334, was modelled using the extension of Equation 6 that is provided in the supplementary material. The two-site competitive binding model, including correction for PHNO mass on D3 binding and a small specific signal in the cerebellum, was applied to the measured data before and after motion correction. The $BP_{ND}$ values
obtained before motion correction, and after applying the FBF and GIR algorithms, are shown in Figure 5A for each of the six target ROIs, together with the competitive binding model fits. Motion correction using the proposed GIR algorithm avoided the convergence problems that led to data points with unrealistic values, which occurred with uncorrected and FBF corrected PET data.

In practice, to maintain the integrity at the study level, it is possible (though not ideal) to remove the outliers with appropriate testing. Here we considered $BP_{ND}$ values greater than 10 as outliers. In Figure 5B, the competitive binding model fits are shown using $BP_{ND}$ before motion correction with outliers excluded, $BP_{ND}$ after FBF with outliers excluded, and $BP_{ND}$ estimates obtained directly from the GIR algorithm with no exclusions. Even with all this extra help for the other methods, GIR still produces the best fit to the competitive binding data as judged by its ability to achieve the smallest SSQ.

The primary outcome measures of this study, $EC_{50}^{drug,D_3}$ and $EC_{50}^{drug,D_2}$ of GSK618334, estimated using Equation 6, are presented along with 95% confidence intervals in Table 2.

The $EC_{50}$ estimates obtained following GIR are in the range of the values obtained before motion correction with the removal of unrealistic $BP_{ND}$ data points (the ones with significant subject motion) and have smaller confidence intervals.

4. Discussion
Image based registration methods are frequently used in brain PET studies to minimise the impact of subject movement on the outcome measures derived from tracer kinetic analysis. In this work we have investigated and evaluated the applicability of two such motion correction algorithms for dynamic PET data obtained as part of a clinical dopamine D3/D2 receptor occupancy study with GSK618334.

This involved a more traditional FBF approach along with a novel GIR method that we have recently introduced. The GIR approach incorporates a pharmacokinetic model into the registration process so as to provide additional temporal constraints in the registration process over and above just spatial image similarity maximisation. The input function for the pharmacokinetic model is derived directly from the tomographic PET data using a reference region and therefore the GIR method does not necessarily require any arterial blood sampling. We hypothesised that the application of a spatio-temporal (GIR) method that makes better use of the available data would lead to improved results over the purely spatial (FBF) method.

The performance of the FBF and GIR methods was evaluated using data from a dopamine D3/D2 receptor occupancy study in humans with [11C]-(+)-PHNO. In the PET data there were different levels of subject motion and a range of signal-to-noise ratios (SNR) due to competitive binding of the drug at varying doses. The performance was assessed directly by visual inspection of the PET data, and indirectly by assessing the inter-subject variability in baseline $BP_{ND}$, convergence and residuals of the competitive binding modelling, as well as the drug $EC_{50}$ estimation. In addition to the visually improved removal of subject motion, the GIR method led to more reliable $BP_{ND}$ estimates with reduced variation and bias at baseline and when modelling competitive binding of GSK618334 as compared to the FBF method. It also provided estimates of GSK618334 $EC_{50}$ that were consistent
with a previously published study that had employed outlier removal techniques, but with reduced confidence intervals [19]. These convergent data all provide evidence that the proposed GIR method yields improved registration for dynamic PET data. On the study level, it increases the statistical power by reducing the motion-introduced variability, and in practice less PET scans would be required to achieve the same outcome parameter precision once the motion correction is accurately conducted using the GIR method.

The proposed GIR method uses the full dynamic data in addition to spatial similarity and from a theoretical point of view it should perform better than the FBF method. For brain D3/D2 images, whilst there is limited binding data outside the striatum, there is still information available from the delivery and washout to regions just containing free and non-specifically bound tracer. Similarly, for other tracers with different distributions, areas of relatively low signal may still contribute usefully to the motion correction process. The pharmacokinetic model employed by the GIR approach is generic allowing for different compartmental topologies at individual voxels and thus should not only handle the kinetics displayed by a broad range of tracers, but even different kinetic behaviour in different regions of the image. Furthermore, it is not necessary for the reference region to be devoid of the target biology, as the data can be quantified subsequently, and a region with the fastest kinetics could be used as the reference region. Thus, the method should be generally applicable to dynamic brain PET data (except perhaps when significant metabolite components contribute to the data). The generalised reference tissue model employed is able to describe a range of different behaviours, which will likely include regions outside the brain. Qualifying how well it is able to describe such data is not strictly necessary in order to assess the performance of the approach (for instance it would not matter if it did not describe these regions particularly well if the algorithm provides improved
performance in image registration over existing approaches). Future studies will explore the utility of the approach with other tracers and further extension to the deformation motion model could also allow application to dynamic imaging outside the brain as well.

In this paper we have employed filtered back projection (FBP) for reconstruction of the dynamic image sequence. We fully acknowledge that the application of iterative reconstruction algorithms could have improved the performance of both the FBF and GIR approaches but an assessment of this was beyond the scope of this paper. Future studies will evaluate the impact of the reconstruction algorithm in more detail. Our hypothesis is firstly that the application of iterative reconstruction algorithms to the FBF method would bring its performance closer to that of the current GIR (FBP) method and secondly that the application of iterative reconstruction to the GIR method would further increase its performance.

The reconstructed PET data used in this work represents a very common clinical workflow. In practice the subject motion introduces mismatched attenuation and scatter correction in the reconstruction, which are theoretically challenging to eliminate with post reconstruction approaches. Addressing these issues, however, requires access to the raw PET emission data and extra fast-processing hardware/software that would impose an undesirable cost for clinical use. The approach proposed in this work is directly based on the reconstructed PET images and in the presence of intra-frame motion artefacts (attenuation, scatter etc), it demonstrates an improvement in the kinetic analysis of dynamic data compared to alternative image-based methods. Further extension of this approach to fully account for attenuation/scatter mismatch in the PET reconstruction framework will be explored and evaluated in future work.
Besides the image-based motion correction methods discussed in this work, which estimate and eliminate the subject motion using only the measured PET data, subject motion can also be tracked and corrected using additional hardware. However such motion-tracking systems are not always available in typical clinical settings, and additional processing and calibration are required to ensure the mapping of the motion parameters from the motion-tracking space into the PET image space is accurate. The image-based methods presented provide a more accessible and less demanding way to remove the subject motion in the majority of PET studies.

In summary, we have demonstrated the applicability of a novel groupwise based imaged registration for improving the quality of data obtained from PET receptor occupancy studies, using only measured PET data. The generic nature of the incorporated pharmacokinetic model means that this should have wide utility across PET neuroimaging studies.

5. Conclusions

Groupwise image based registration of dynamic brain PET data provides an improved method to correct for subject motion. Incorporation of a reference input-based general pharmacokinetic model that requires no arterial blood sampling allows for wide applicability of the technique. The approach has value for increasing the integrity of both individual scan data and outcome measures from clinical studies involving a series of scans enabling increased precision or reduction in the required number of scans.

6. Competing interests

The authors declare that they have no competing interests.
7. **Authors' contributions**

Image processing and data analysis were performed by JJ and GES. JAS and RNG conceived the study, participated in its design and coordination, and helped to draft the manuscript. All authors read and approved the final manuscript.

8. **Acknowledgement**

We would like to acknowledge GlaxoSmithKline for the provision of the data. Jieqing Jiao has received funding from the Chinese Ministry of Education - University of Oxford Scholarships, the GlaxoSmithKline Clinical Imaging Centre, and the Cancer Research UK / EPSRC Cancer Imaging Centre at Oxford.

9. **References**

1. Ruttimann UE, Andreason PJ, Rio D. Head Motion during Positron Emission Tomography - Is It Significant. Psychiat Res-Neuroim. 1995;61(1):43-51. doi:10.1016/0925-4927(95)02565-F.
2. Bloomfield PM, Spinks TJ, Reed J, Schnorr L, Westrip AM, Livieratos L et al. The design and implementation of a motion correction scheme for neurological PET. Phys Med Biol. 2003;48(8):959-78. doi:S0031-9155(03)57840-X.
3. Buhler P, Just U, Will E, Kotzerke J, van den Hoff J. An accurate method for correction of head movement in PET. Ieee T Med Imaging. 2004;23(9):1176-85. doi:10.1109/Tmi.2004.831214.
4. Herzog H, Tellmann L, Fulton R, I S, Kops ER, Bente K et al. Motion artifact reduction on parametric PET images of neuroreceptor binding. J Nucl Med. 2005;46(6):1059-65.
5. Mourik JEM, Lubberink M, van Velden FHP, Lammertsma AA, Boellaard R. Off-line motion correction methods for multi-frame PET data. J Cerebr Blood F Met. 2009;29:S330-S.
6. Costes N, Dagher A, Larcher K, Evans AC, Collins DL, Reilhac A. Motion correction of multi-frame PET data in neuroreceptor mapping: Simulation based validation. Neuroimage. 2009;47(4):1496-505. doi:10.1016/j.neuroimage.2009.05.052.
7. Keller SH, Sibomana M, Olesen OV, Svarer C, Holm S, Andersen FL et al. Methods for Motion Correction Evaluation Using F-18-FDG Human Brain
Scans on a High-Resolution PET Scanner. J Nucl Med. 2012;53(3):495-504. doi:10.2967/jnumed.111.095240.

8. Wardak M, Wong KP, Shao W, Dahlbom M, Kepe V, Satyamurthy N et al. Movement Correction Method for Human Brain PET Images: Application to Quantitative Analysis of Dynamic F-18-FDDNP Scans. J Nucl Med. 2010;51(2):210-8. doi:10.2967/jnumed.109.063701.

9. Bailer UF, Frank GK, Price JC, Meltzer CC, Becker C, Mathis CA et al. Interaction between serotonin transporter and dopamine D2/D3 receptor radioligand measures is associated with harm avoidant symptoms in anorexia and bulimia nervosa. Psychiatr Res-Neuroim. 2013;211(2):160-8. doi:10.1016/j.psychresns.2012.06.010.

10. Bohnen NI, Muller MLTM, Kotagal V, Koepp RA, Kilbourn MR, Gilman S et al. Heterogeneity of cholinergic denervation in Parkinson's disease without dementia. J Cerebr Blood F Met. 2012;32(8):1609-17. doi:10.1038/jcbfm.2012.60.

11. Kreisl WC, Liow JS, Kimura N, Seneca N, Zoghbi SS, Morse CL et al. P-Glycoprotein Function at the Blood-Brain Barrier in Humans Can Be Quantified with the Substrate Radiotracer C-11-N-Desmethyl-Loperamide. J Nucl Med. 2010;51(4):559-66. doi:10.2967/jnumed.109.070151.

12. Petrou M, Bohnen NI, Muller MLTM, Koepp RA, Albin RL, Frey KA. A beta-amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology. 2012;79(11):1161-7.

13. Catafau AM, Searle GE, Bullich S, Gunn RN, Rabiner EA, Herance R et al. Imaging cortical dopamine D-1 receptors using [C-11]NNC112 and ketanserin blockade of the 5-HT2A receptors. J Cerebr Blood F Met. 2010;30(5):985-93. doi:10.1038/jcbfm.2009.269.

14. Etrup A, da Cunha-Bang S, McMahon B, Lehel S, Dyssegaard A, Skibsted AW et al. Serotonin 2A receptor agonist binding in the human brain with [C-11]Cimbi-36. J Cerebr Blood F Met. 2014;34(7):1188-96. doi:10.1038/jcbfm.2014.68.

15. Donahue MJ, Sideso E, MacIntosh BJ, Kennedy J, Handa A, Jezzard P. Absolute arterial cerebral blood volume quantification using inflow vascular-space-occupancy with dynamic subtraction magnetic resonance imaging. J Cerebr Blood F Met. 2010;30(7):1329-42. doi:10.1038/jcbfm.2010.16.

16. Montgomery AJ, Thielemans K, Mehta MA, Turkheimer F, Mustafovic S, Girasby PM. Correction of head movement on PET studies: Comparison of methods. J Nucl Med. 2006;47(12):1936-44.

17. Jiao JQ, Schnabel JA, Gunn RN. A Generalised Spatio-Temporal Registration Framework for Dynamic PET Data: Application to Neuroreceptor Imaging. Lect Notes Comput Sc. 2013;8149:211-8.

18. Jiao JQ, Searle GE, Tziortzi AC, Salinas CA, Gunn RN, Schnabel JA. Spatio-temporal pharmacokinetic model based registration of 4D PET
neuroimaging data. Neuroimage. 2014;84:225-35. doi:Doi 10.1016/J.Neuroimage.2013.08.031.
19. Searle GE, Beaver JD, Tziortzi A, Comley RA, Bani M, Ghibellini G et al. Mathematical modelling of [C-11]-(+)-PHNO human competition studies. Neuroimage. 2013;68:119-32. doi:Doi 10.1016/J.Neuroimage.2012.11.033.
20. Gunn RN, Gunn SR, Turkheimer FE, Aston JAD, Cunningham TJ. Positron emission tomography compartmental models: A basis pursuit strategy for kinetic modeling. J Cerebr Blood F Met. 2002;22(12):1425-39. doi:Doi 10.1097/01.Wcb.0000045042.03034.42.
21. Yaqub M, Boellaard R, Kropholler MA, Lammertsma AA. Optimization algorithms and weighting factors for analysis of dynamic PET studies. Phys Med Biol. 2006;51(17):4217-32. doi:Doi 10.1088/0031-9155/51/17/007.
22. Tziortzi AC, Searle GE, Tzimopoulou S, Salinas C, Beaver JD, Jenkinson M et al. Imaging dopamine receptors in humans with [C-11]-(+)-PHNO: Dissection of D3 signal and anatomy. Neuroimage. 2011;54(1):264-77. doi:Doi 10.1016/J.Neuroimage.2010.06.044.
Table 1. The inter-subject variability ($CV$) in baseline $BP_{ND}$ before and after motion correction (MC). Unrealistically large $V_T$ values due to unsuccessful convergence in 2TC kinetic parameter estimation as a result of uncorrected motion artefacts were removed. ROI sizes are given in cm$^3$.

| Region (ROI size) | SN (0.3 cm$^3$) | GP (0.8 cm$^3$) | VST (1.0 cm$^3$) | CD (2.8 cm$^3$) | PU (4.2 cm$^3$) | TH (5.3 cm$^3$) |
|------------------|----------------|----------------|------------------|----------------|----------------|----------------|
| $CV$ before MC$^1$ | 0.3699 | 0.3405 | 0.6345 | 0.2825 | 0.2627 | 0.5172 |
| $CV$ after FBF$^2$ | 0.1785 | 0.7411 | 0.2857 | 0.1173 | 0.0848 | 0.1630 |
| $CV$ after GIR | 0.1523 | 0.0896 | 0.1822 | 0.0962 | 0.0772 | 0.1606 |

$^1$ 2 outlier values removed

$^2$ 3 outlier values removed
Table 2. $EC_{50}^{\text{drug,D3}}$ and $EC_{50}^{\text{drug,D2}}$ for GSK618334 estimated before and after motion correction (MC). Values in parentheses indicate 95% confidence intervals associated with the parameter estimates.

| MC Method | Removal of unrealistic $BP_{ND}$ data points | $EC_{50}^{\text{drug,D3}}$ of GSK618334 (ng/ml) | $EC_{50}^{\text{drug,D2}}$ of GSK618334 (ng/ml) |
|-----------|---------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| No MC     | Required                                     | 15 (-6, 37)                                   | 529 (206, 852)                                |
| MC by FBF | Required                                     | 4 (0, 8)                                      | 492 (327, 658)                                |
| MC by GIR | Not necessary                                 | 10 (5, 15)                                    | 539 (419, 660)                                |
Titles and legends to figures

Figure 1. Schematic illustration of the proposed groupwise image registration (GIR) algorithm for motion correction. With the initialisation in Step 1, the algorithm repeats Step 2-5 until convergence and returns the final motion corrected dynamic PET data in Step 6.

Figure 2. Summary of displacements introduced by FBF and GIR MC methods for [11C]-(+)-PHNO PET occupancy study data. In each box, the central mark denotes the median, the edges of the box are the 25th and 75th percentiles, the whiskers extend to the most extreme data points not considered to be outliers, and outliers are plotted individually using the symbol +. Subjects (S1-S8) exhibited various degrees of motion during the scans. The scans marked with grey background had visually negligible motion following assessment by an observer viewing the data in the movie mode in FSLview. For these scans the FBF method introduced up to 5 mm displacement, whereas the displacement introduced by the GIR method was at a sub-voxel level. Plasma concentration of GSK618334 is also shown for each scan.
Figure 3. Selected temporal frames from a sagittal slice from subject 2’s baseline [11C]-(+)-PHNO data. Times are mid-frame times. (A) before motion correction, (B) after motion correction by the conventional FBF algorithm, and (C) after motion correction by the proposed GIR algorithm. Units are kBq/ml. (D) TACs from voxels in dorsal caudate and globus pallidus, depicted in colours corresponding to the voxels shown in A), B) and C), which are spatially fixed to demonstrate the displacement. The subject exhibited obvious rotation of ~10 degree, as shown on the sagittal slices in A), which was corrected by the proposed method, as shown in C). The TACs for these regions were also obtained from all eight healthy subjects’ baseline data after motion correction, and the population TACs were generated by averaging TACs normalised for [11C]-(+)-PHNO dose and subject weight. These population TACs were scaled to match subject 2’s baseline data and are shown in D). The tracer kinetics showed consistency with the population data after GIR motion correction. The scan had no GSK618334 taken and the [11C]-(+)-PHNO injected activity was 384.9 MBq (injected mass 4.24 ug).

Figure 4. Selected temporal frames from a sagittal slice from subject 2’s follow-up [11C]-(+)-PHNO data. Times are mid-frame times. (A) before motion correction, (B) after motion correction by the conventional FBF algorithm, and (C) after motion correction by the proposed GIR algorithm. Units are kBq/ml. The GSK618334 plasma concentration in the scan was 58.2 ng/ml, and the [11C]-(+)-PHNO injected activity was 139.8 MBq (injected mass 2.35 ug).
Figure 5. Competitive binding analysis of [11C]-(+)-PHNO data. (A) Fits (shown as curves) to the baseline and post-dose data before and after motion correction by FBF and GIR (shown as circles, crosses and stars) using a competitive binding model with unweighted $BP_{ND}$ data. The unweighted sum of squared differences (SSQ) of the competitive model fitting was calculated for each $BP_{ND}$ data set, and was then scaled to the SSQ of data before motion correction so that SSQ_{motion}=1. Other than for the GIR approach all methods resulted in some unrealistic estimates of $BP_{ND}$ that affected the fits. (B) Competitive model fits of $BP_{ND}$ data points derived from PET data before MC with removal of unrealistic values; after MC by FBF with removal of unrealistic values; after only MC by the proposed GIR.
Figure 1

Figure 2
Figure 3

Figure 4
Figure 5A

Figure 5B